In combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread of breast cancer in some patients with a certain type of aggressive tumor.
Previous winners are not eligible for nomination, but previous finalists may be nominated. 2025 Excellence in Health Care Career Achievement Award Dr. William Goggins Community Achievement iHEART Collaborative The Restoracy Transplant Optimization Program Physician Dr. Nasser Hanna Pharmacist Dawn Moore Innovations in Healthcare Community Heart and Vascular Hospital Electrophysiology Program Intersurgical Inc. Mental Health Advocacy […]
Eli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
Dr. Alexander B. Niculescu, a psychiatrist at the IU School of Medicine, has won a five-year, $1.5 million grant from the National Institutes of Health to hunt for the presence of certain proteins in the blood that would indicate that a patient suffers from a mood disorder, which afflicts one in five Americans.
The city’s plan to provide an $86 million loan for the mixed-use North of South real estate development adjacent to the Eli Lilly and Co. campus has drawn criticism from those who think the city should focus first on other needs, such as IndyGo and public libraries.
Indianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150 million plan to expand it.
Eli Lilly and Co. paid more than $102 million last year and early this year to physicians for talking up Lilly drugs to other doctors. Yet 88 of the doctors Lilly pays have been sanctioned by state medical boards.
Clarian Health Plans will add rival Community Health Network to its list of providers approved for Clarian’s Medicare Advantage customers. Beginning Jan. 1, Clarian’s health plan customers are approved to see one of Community’s 700 physicians or receive care at one of its five Indianapolis-area hospitals. Clarian Health Plans, started in 2008 as a subsidiary of the Clarian Health hospital system, administers a Medicare Advantage plan in 32 Indiana counties.
Biomet Inc. narrowed its loss in the three months ended Aug. 31 as sales rose everywhere but in Europe. The Warsaw-based maker of orthopedic implants lost $18 million in its fiscal first quarter, down from a loss of $23 million in the same quarter a year ago. Excluding special accounting charges, the company would have turned a quarterly profit of $51 million, a 3-percent increase over the same quarter last year, when special charges also were excluded. Biomet’s total sales for the quarter rose 2 percent to $641 million, with a 5-percent advance in the United State and an 11-percent rise in international markets outside Europe. Sales in Europe fell 11 percent.
Lt. Gov. Becky Skillman and the Indiana Rural Health Association launched the Indiana Telehealth Network last week, a $7 million project that will connect 22 rural Indiana hospitals with fiber-optic broadband communication lines. The network is designed to grow the use of telemedicine, where patients in remote areas could have online consultations with specialty physicians in more populous areas. The Federal Communications Commission will fund 85 percent of the project, with local funds providing the balance. The hospitals in the network are in such towns as Monticello, Tipton, Boonville and Greencastle. Indianapolis-based Clarian Health and Community Health Network will also be connected to the rural hospitals.
INphoton Inc. and two researchers at the Indiana University School of Medicine have received a $1 million Small Business Technology Transfer grant to commercialize its imaging services for pharmaceutical and life sciences companies. INphoton uses powerful light miscroscopes to analyze and produce 3-D images of activities in living cells within the human body. INphoton is led by former Eli Lilly and Co. executive Steve Plump.
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
Stock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
Eli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage study, the second setback for a Lilly diabetes drug candidate in two days.
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
The Hancock County community is drawing interest because of recent hiring in the area and a strong population of seniors.
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
IU Hospital soon will receive the catchy new name Indiana University Health University Hospital as part of Clarian Health’s 2011 name change to Indiana University Health. Clarian announced new names for all 17 of its hospitals on Tuesday, saying the names would change in early 2011. Methodist Hospital, for example, will be called Indiana University Health Methodist Hospital—at least inside the halls of Clarian’s offices. Outside it? That’s hard to say. The only hospital that won’t get the “IU Health” tag added before its name is Riley Hospital for Children, which will be known as Riley Hospital for Children at Indiana University Health.
A new estimate has lowered the expected cost of the federal health care overhaul to Indiana's state government to perhaps $2.6 billion over the next decade — $1 billion less than an initial projection made last spring, according to the Associated Press. Robert Damler of the Seattle-based actuarial consulting firm Milliman Inc. told the state's Medicaid oversight commission on Monday that new information provided by the federal government will drop the possible costs an additional $330 million. The firm in May had lowered its initial estimate to $2.9 billion. The latest change is because the Centers for Medicare and Medicaid Services in late September changed its interpretation of the law regarding a prescription rebate program. In spite of Democratic criticism, Damler declined to remove an estimated $600 million in costs from the report that could come as a result of increased physician reimbursements.
Analysts think Eli Lilly and Co. may try to acquire its partner, San Diego-based Amylin Pharmaceuticals Inc., or chase companies with more approved products to offset repeated setbacks in bringing its pipeline drugs to market, reported Bloomberg News. From Amylin, Indianapolis-based Lilly would gain full control of the diabetes drug Byetta and a longer-acting version called Bydureon that was delayed last week by U.S. regulators. Another option for Lilly would be to build on its painkiller products, such as Cymbalta, by acquiring Pennsylvania-based Cephalon Inc. or Newark, N.J.-based Endo Pharmaceuticals Inc. By 2013, Lilly loses patents on medicines responsible for nearly half its revenue.
Indianapolis-based Home Health Depot Inc. said on Thursday it has acquired the Home Health Care Products LLC subsidiary of Arcadia Resources Inc., also headquartered here. Terms of the deal were not disclosed. Home Health Care Products sells mobility tools, respiratory devices, bathroom-safety and home-modification products, as well as daily living aids. Home Health Depot was founded in 1998 and purchased by CEO David Hartley in 2004. It has grown from a single office in Greenwood to 12 locations in Indiana and Illinois—increasing annual revenue from $300,000 to more than $6.7 million. The company has more than 100 employees.
OrthoIndy opened a new branch of its Indiana Orthopaedic Hospital in Greenwood. It will serve as a practice location for 21 physicians. Outpatient surgeries will begin in spring 2011. The new location will effectively replace OrthoIndy’s offices at the St. Francis Indianapolis Hospital near Interstate 65 and Emerson Avenue. St. Francis has sued some of the doctors involved in the new OrthoIndy location for breach of contract.
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
The position at United Way of Central Indiana had been vacant because of budget issues.
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
